RAFAEL HOLDINGS INC-CLASS B

RFLNYSE

🏆 #3439 by market capEarnings Oct 28US Equity

$1.92▼ $0.07 (−3.52%)

🌅 Pre-market$1.90▼ 1.04%Regular close · extended-hours price shown

1h—

24h▼ 3.5%

7d▼ 6.6%

14d▼ 2.0%

30d▼ 16.2%

1y▲ 16.4%

🏦Market Cap

$100M

Small Cap

📈Revenue Growth (YoY)

+33.9%

High Growth

📊Gross Margin

95.1%

High

💵FCF Margin

—

⚖️P/S Ratio

104.0x

Expensive

Otter Score

Fair

Trading Snapshot

Day Range: $1.90 – $1.94
52-Week Range: $1.12 – $3.96
Volume: $3.75B
Avg Volume: $3.24B
Shares Outstanding: 52.0M
Next Earnings: Sep 14, 2026

Fundamentals Snapshot

Annual Revenue: $917,000
Last Q Revenue: $179,000
P/E Ratio: —
P/S Ratio: 104.0x
EPS (TTM): $-0.68
Dividend Yield: —

Why Investors Own RFL

✓High-growth profile — revenue up +21.1% YoY with expanding US Equity exposure.
✓Healthy economics — 44% gross margin and 18% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$917,000▲ +18.9% YoY

Gross Margin (TTM)

44.0%▲ +2.3% YoY

Operating Income (TTM)

$254,009▲ +18.9% YoY

Free Cash Flow (TTM)

$165,060▲ +18.9% YoY

About RAFAEL HOLDINGS INC-CLASS B

Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.

🦦